NEWS
National SMC Approval Still Leaves a 10-Times Gap
An SMC yes is not access in Scotland: GLP-1 rates still differ about 10 times by NHS board, and most weight-loss jabs are bought privately.
GLP-1 prescribing in the Western Isles ran at 1,086.54 quantity units per 100,000 GP-registered people in June to August 2025, about 10 times Shetland’s 100.31, in the first multi-class study of how Scotland uses drugs the Scottish Medicines Consortium has already accepted. The Association of the British Pharmaceutical Industry, backed by LCP Health, published the figures on 29 October 2026 from NHS community and hospital data covering all 14 territorial boards from September 2020 to August 2025.
The SMC exists so a national yes would replace 14 local ones. The gap the report measures sits after that yes, in formularies, specialist clinics and a private market for weight-loss jabs.
The National Yes Still Needs 14 Local Ones
The consortium has, since January 2002, given NHS boards a single verdict on whether a new medicine works and is worth the money. Its own account of how the SMC decides which medicines to accept is blunt: once it accepts a drug, boards are expected to make that medicine, or an equivalent, available, and to publish what they have included or left off their lists.
Each board still runs that last step through its Area Drug and Therapeutics Committee. The committee weighs place in therapy, a local protocol, and what the service can staff and pay for. A national acceptance is the start of that path, the ABPI report says, not the end of it.
The study, analysing the adoption of SMC-accepted medicines in Scotland, tracked five classes: GLP-1 and dual GIP/GLP-1 drugs for type 2 diabetes and weight management; non-statin LDL-lowering medicines; ALK inhibitors for non-small cell lung cancer; CGRP drugs for migraine prevention; and an orphan medicine for obstructive hypertrophic cardiomyopathy. Variation was widest where diagnosis, genomic tests, monitoring or a specialist team had to be in place before a prescription could be written.
In Scotland, everyone should have equitable access to medicines the Scottish Medicines Consortium has already judged effective and good value.
Our new report, supported by @LCPHealth, compares prescribing across all 14 NHS boards. https://t.co/MtP67ReBla #MedicinesAccess… pic.twitter.com/0604vVuM6f
— ABPI (@ABPI_UK) October 29, 2026
ABPI member companies told the authors that some GPs will not start injectable therapy unless a local service is commissioned and paid for. That is an industry account, and the trade body wants faster uptake. The same stall shows up in board documents and in what patients actually buy.
Western Isles Prescribes GLP-1s at 10 Times Shetland’s Rate
Across Scotland, population-standardised GLP-1 quantity rose by about 430 per cent over the five years, from around 50 per 100,000 GP-registered people in September 2020 to more than 265 by August 2025. The national climb did not even out the map. The Western Isles rate was almost three times Greater Glasgow and Clyde’s 392.97, the next highest board, and the island boards at both ends of the range are small enough that a few extra packs move the rate a long way.
GLP-1 PRESCRIBING BY NHS BOARD, JUNE TO AUGUST 2025
| NHS board | Three-month average quantity per 100,000 |
|---|---|
| Western Isles | 1,086.54 |
| Greater Glasgow and Clyde | 392.97 |
| Highland | 356.41 |
| Orkney | 310.89 |
| Tayside | 300.66 |
| Lothian | 256.45 |
| Borders | 231.67 |
| Lanarkshire | 190.21 |
| Dumfries and Galloway | 153.82 |
| Grampian | 151.13 |
| Ayrshire and Arran | 135.67 |
| Fife | 126.49 |
| Forth Valley | 123.20 |
| Shetland | 100.31 |
The unit is quantity supplied, not patients treated, and it mixes diabetes use with weight-management use because the datasets cannot split the two. Private prescriptions are missing. NHS Western Isles said it built a structured GLP-1 path earlier than any other board and that the rate reflects that work and local clinical need, not a later pilot.
Our prescribing rates reflect that early implementation, as well as local clinical need, rather than participation in a pilot scheme.
NHS Western Isles statement
The board added that the drugs sit inside a dietetic-led programme and that patients are reporting clinical benefit. Company feedback in the report said formulary delays in some areas ran past a year after SMC acceptance.
Why Glasgow Outpaces Boards With Higher Obesity
Need on paper does not line up with the table. In 2024 about 5.9 per cent of people in Scotland had diagnosed type 2 diabetes, 88.2 per cent of all diagnosed diabetes, and 31 per cent of adults were living with obesity. About 87 per cent of adults with type 2 diabetes were overweight or obese. Obesity still tracks deprivation, at 24 per cent in the least deprived fifth of areas and 36 per cent in each of the two most deprived fifths.
Greater Glasgow and Clyde had the second-lowest overweight and obesity prevalence among boards, at 65 per cent, and the second-highest GLP-1 rate. The Western Isles had the second-highest prevalence, at 70 per cent, and the fourth-lowest age-standardised diagnosed diabetes rate, at 5.6 per cent. Shetland had the lowest prescribing despite relatively high overweight and obesity.
Boards whose populations sit in the most deprived fifth generally recorded higher NHS GLP-1 use, which fits the disease pattern. The authors warn that less deprived boards may also be sending more people into the private market, so the NHS numbers cannot be read as fair access to obesity treatment. Public Health Scotland’s dispenser payments analysis for 2025/26 already put semaglutide’s gross ingredient cost at £26.72 million, second only to glucose sensors, which is one reason local finance teams treat each new path as a budget event.
One Lipid Clinic for a Vast Highland Patch
Non-statin LDL-lowering medicines accepted for people with high cholesterol or mixed dyslipidaemia showed the next-widest spread. By the end of the study, rates differed eight- to 10-fold between Highland, the highest, and Forth Valley, the lowest, and they ran higher in the west of Scotland than in the east. The LDL analysis did not adjust for how ill local patients were or how services were built, so it is a signal, not a scorecard.
WHAT THE CHOLESTEROL DATA SHOW
- The spread: Highland’s per-person rate was eight- to 10-fold Forth Valley’s by June to August 2025.
- The disease: In 2024 an estimated 16 per cent of adults reported some form of cardiovascular disease, rising to more than 40 per cent at age 75 and over.
- The clinic model: Specialist lipid clinics sit in hospitals and run as small teams; boards with clearer links from those teams to GPs recorded more prescribing.
- The catch inside one board: NHS Highland’s high rate comes from a single clinic covering a large rural area, so people who live nearer the clinic may account for much of the use.
For cancer, migraine and the cardiomyopathy medicine, the report is thinner on board-by-board rates and clearer on the mechanism: when a drug needs a test, a specialist starter, or a regional centre, recorded prescribing follows the centre, not the patient’s home board. One of the seven asks is to track those medicines by where people live.
Patients Buy Most Weight-Loss Jabs Privately
The NHS figures are a poor proxy for obesity treatment. Among Scottish respondents who had used weight-loss medication in the previous 12 months, 71 per cent said they got it privately, against an estimated 85 per cent of UK patients on the same class. SMC acceptance for obesity use was published in June 2024, with national consensus that boards should phase the drugs in, starting with people whose BMI is at least 38 and who have at least one weight-related condition. Tirzepatide (Mounjaro) had been accepted for weight loss in 2023 and semaglutide (Wegovy) in 2024.
Freedom of information returns from boards showed 705 people had received injections for weight loss on the NHS by September 2026. NHS Western Isles had 340 of them, the most of any board in the pilots. Nine territorial boards said they did not routinely prescribe for weight loss, though some were drawing up paths. NHS Lothian had a proposal for an obesity-medicines path whose first two priority groups came to 517 people. NHS Lanarkshire had already set a defined start path through its specialist weight service, yet its GLP-1 quantity, at 190.21, sat in the middle of the national table, another sign that the high Western Isles figure is not just an obesity pilot.
THE SIX WEIGHT-LOSS PILOTS
- NHS Western Isles: Early structured path; 340 patients on weight-loss medication by the FOI count.
- NHS Forth Valley: Pilot at Falkirk Community Hospital for people with a BMI of 40 or more plus at least four serious conditions, or who need major surgery; 48 patients on the programme and 18 via GP, with new referrals closed while it runs.
- NHS Borders: Named as a pilot board in the same FOI round.
- NHS Lothian: Urgent-care pilot plus the 517-person first cohorts, with evaluation before any expansion.
- NHS Lanarkshire: Defined initiation path inside the specialist weight-management service.
- NHS State Hospital: The sixth site listed with the territorial pilots.
Claire Colligan, NHS Forth Valley’s associate director of pharmacy for primary and community care, said it is frustrating for people to know the medicines are available and still be unable to get them on the NHS, and that the drugs are not going away. Dr Mark Strachan, a diabetes specialist and president of the Royal College of Physicians, called the lack of access for people at highest risk discriminatory, and said the NHS spends huge sums treating obesity’s complications rather than the obesity. Kathleen McClaughlin, 54, from Laurieston, lost four stone (13 per cent of her body weight) on the Forth Valley programme after her gynaecologist referred her so she could have surgery; she had refused to pay privately because she wanted clinical support beside her.
NHS Highland, third in the GLP-1 quantity table, is still not recommending weight-management medicines yet while it writes local paths. It has accepted Wegovy onto the formulary but will not use it until those paths exist, and it has had no request to add Mounjaro. The SMC yes is on the books. The prescription is not.
A Year Can Pass Before a Drug Hits a Local List
National guidance has required speed on paper for 14 years. Chief Medical Officer letter CMO(2012)1, issued on 13 February 2012 to tighten CEL 17 (2010), told boards to reach a 90-day formulary decision and 14-day publication after SMC advice goes to boards. That advice is confidential for the first month. The SMC now also shares its decision with boards four weeks before publication so committees can prepare. The ABPI report still found GLP-1 formulary waits of more than a year in some areas, and it could not even date formulary inclusion from the prescribing files it used.
HOW THE CLOCK WAS SUPPOSED TO RUN
- January 2002: The SMC starts, so 14 Area Drug and Therapeutics Committees are not each appraising the same new drug.
- 2010: CEL 17 tells boards that an SMC-accepted medicine, or its equivalent, should be made available.
- 13 February 2012: CMO(2012)1 sets the 90-day decision clock and the 14-day publication rule, with standard labels for included, pending protocol, or not included.
- 18 July 2025: The Chief Medical Officer’s office publishes a refreshed Common Understanding on NHS-industry working, the third version after 2003 and 2012.
- 29 October 2026: The ABPI-LCP analysis finds the implementation gap still sitting in local lists, clinics and budgets.
Jackie Baillie, Scottish Labour’s health spokesperson, said the country cannot have people facing a postcode lottery for medication, and that the report had identified an implementation gap between SMC approval and adoption across NHS Scotland. Victoria Jordan, ABPI executive director of patient access, put the same point from the industry side.
Scotland has a strong and respected system for assessing new medicines. But this report shows that the use of some accepted medicines can vary widely between NHS boards, and that differences in patient need do not fully explain this. While the data we have does not tell us everything, it does show we need to look more closely at this issue. When avoidable barriers slow things down, patients can wait longer than they should for medicines already judged effective and good value.
Victoria Jordan, Executive Director of Patient Access, ABPI
Seven Recommendations Meet a Plan to Cut Variation
The report does not rank boards and cannot explain any one area. It asks the Scottish Government and NHS Scotland to lead seven changes, using the Common Understanding 2025 cooperation framework and a “triple helix” of government, NHS, academia and industry. Caroline Lamb, director general for health and social care, introduced that framework in July 2025 as an update of guidance first issued in 2003.
THE SEVEN RECOMMENDATIONS
- Earlier planning: Share horizon-scanning detail on staff, tests, paths and money before SMC advice is published, building on UK PharmaScan, the SMC Forward Look and the Horizon Scanning Advisory Board.
- Open lists: Publish up-to-date formularies, inclusion decisions and, where relevant, how long implementation will take, in line with CEL 17, and use East and West Planning Groups and regional formularies to cut duplicate work.
- Checks on complex drugs: A national, proportionate assurance process for medicines that need new diagnostics, workforce or cross-board paths, without replacing local clinical decisions.
- A learning loop: Test whether that earlier planning actually gets medicines into use sooner.
- Home-board tracking: Count specialised medicines by where patients live, not only where a regional centre records the dose.
- Joint working: Use the Common Understanding and the triple helix for horizon scanning, service planning and evidence, while keeping appraisal independent.
- Protected funding: Pilot ring-fenced money for a few high-impact SMC-accepted medicines where local budget pressure could delay listing, because boards are still expected to pay from general allocations.
A Scottish Government spokesperson said ministers will carefully consider the findings, and that health-board reforms are intended to improve equity of access and reduce unwarranted variation and bureaucratic barriers. Public Health Minister Maree Todd, speaking when the FOI weight-loss numbers landed in mid-October, said individual boards decide how obesity medicines are put in place, guided by the national consensus on a phased rollout by BMI and related conditions.
The Western Isles already wrote a path and prescribed. Highland listed Wegovy and waited for a path. Shetland’s GLP-1 quantity stayed at 100.31. The SMC verdict on those drugs did not change between those boards. The local list, the clinic and the private invoice did.
Disclaimer: This article is news reporting and analysis of an industry-funded study of NHS prescribing, and it is for information only. It is not medical advice, not a recommendation to start or stop any medicine, and not a guide to who should receive GLP-1, cholesterol or other specialist drugs. Readers who think they may be eligible for treatment should speak to their GP, specialist or NHS weight-management or lipid service, and should not use these board-level rates to judge their own care. Figures and service statuses are those given in the cited NHS, government and ABPI material as dated in the piece, and both prescribing patterns and local pathways can change.
-
AUTO2 months agoVolkswagen Sells the Osnabruck Plant to Clear a Board Fight
-
NEWS3 months agoApple’s Foldable iPhone Hinges on Samsung Display Supply
-
BUSINESS3 months agoSaksham Gaur Finds He Is His Own Company’s Client
-
AUTO3 months agoTata Motors’ Iveco Tender Opens as Holders Still Decide
-
TECHNOLOGY3 years agoWhat Is SD on Amazon Prime?
-
BUSINESS3 months agoHyderabad 22-Carat Gold Jumps After a False Bargain
-
GAMING3 months agoOnimusha Way of the Sword Preload Hits a Windows 11 Wall
-
BUSINESS3 months agoUltraTech Ultravolt Launch Splits Friday Stocks to Watch
